Were drug design a road, it would surely be a Minnesota street fraught with potholes, ice and gravel.
Even the best ideas can fall by the wayside somewhere between the lab and your corner pharmacy in the process of drug discovery and development.
Recently, University of Minnesota Center for Drug Design member, organic chemist and assistant professor Liqiang Chen, Ph.D., published a paper in the Journal of Medicinal Chemistry outlining the discovery of a potent and selective protein-inhibitor. Blocking the protein, Sirtuin 2 (SIRT2), also has the potential to block a primary contributor to Parkinson’s disease from causing harm.
Even though skin damage may be the furthest thing from your mind right now, don’t let the cool weather fool you. Irreversible skin damage can happen all year round and excessive exposure to the damaging ultraviolet (UV) rays of the sun can have many adverse effects.
So, just wear sunscreen, right? Well, here’s the kicker.
University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.
Complete findings are printed in today’s issue of The Journal of Virology.
The compounds, known as ribonucleoside analogs 8-azaadenosine, formycin A, 3-deazauridine, 5-fluorocytidine and 2’-C-methylcytidine, were found to stop the replication and spread of HIV by blocking HIV DNA synthesis or by inducing lethal mutagenesis.
A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).
The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).
The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found “online first” in the journal Antiviral Chemistry & Chemotherapy.
It might sound like something out of a classic spy thriller, but University of Minnesota researchers are working on a new antidote for one of history’s most lethal chemical agents: cyanide …